TARSUS PHARMACEUTICALS INC (TARS)
US87650L1035 - Common Stock
Taking everything into account, TARS scores 3 out of 10 in our fundamental rating. TARS was compared to 194 industry peers in the Pharmaceuticals industry. The financial health of TARS is average, but there are quite some concerns on its profitability. TARS has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
TARS had negative earnings in the past year.
In the past year TARS has reported a negative cash flow from operations.
TARS had negative earnings in each of the past 5 years.
In the past 5 years TARS reported 4 times negative operating cash flow.
1.2 Ratios
TARS has a Return On Assets (-39.82%) which is comparable to the rest of the industry.
TARS has a Return On Equity of -59.49%. This is comparable to the rest of the industry: TARS outperforms 50.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -39.82% | ||
| ROE | -59.49% | ||
| ROIC | N/A |
ROA(3y)-28.72%
ROA(5y)-21.95%
ROE(3y)-36.49%
ROE(5y)-26.75%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TARS has a Gross Margin of 92.50%. This is amongst the best in the industry. TARS outperforms 96.88% of its industry peers.
TARS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.5% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
TARS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TARS has been increased compared to 1 year ago.
The number of shares outstanding for TARS has been increased compared to 5 years ago.
TARS has a worse debt/assets ratio than last year.
2.2 Solvency
TARS has an Altman-Z score of 7.22. This indicates that TARS is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of TARS (7.22) is better than 83.33% of its industry peers.
TARS has a Debt/Equity ratio of 0.28. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.28, TARS perfoms like the industry average, outperforming 40.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.22 |
ROIC/WACCN/A
WACC9.13%
2.3 Liquidity
A Current Ratio of 7.03 indicates that TARS has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 7.03, TARS is in the better half of the industry, outperforming 76.04% of the companies in the same industry.
A Quick Ratio of 6.99 indicates that TARS has no problem at all paying its short term obligations.
TARS's Quick ratio of 6.99 is fine compared to the rest of the industry. TARS outperforms 77.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.03 | ||
| Quick Ratio | 6.99 |
3. Growth
3.1 Past
TARS shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 0.26%.
The Revenue for TARS has decreased by -32.43% in the past year. This is quite bad
EPS 1Y (TTM)0.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.34%
Revenue 1Y (TTM)-32.43%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%2471.89%
3.2 Future
The Earnings Per Share is expected to grow by 19.25% on average over the next years. This is quite good.
TARS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 137.19% yearly.
EPS Next Y16.52%
EPS Next 2Y23.51%
EPS Next 3Y32.61%
EPS Next 5Y19.25%
Revenue Next Year1551.76%
Revenue Next 2Y436.42%
Revenue Next 3Y266.71%
Revenue Next 5Y137.19%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
TARS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TARS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as TARS's earnings are expected to grow with 32.61% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.51%
EPS Next 3Y32.61%
5. Dividend
5.1 Amount
No dividends for TARS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TARSUS PHARMACEUTICALS INC
NASDAQ:TARS (11/15/2024, 10:01:00 AM)
43.87
-2.78 (-5.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.67B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -39.82% | ||
| ROE | -59.49% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.5% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.22
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 7.03 | ||
| Quick Ratio | 6.99 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)0.26%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y16.52%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-32.43%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y